Revolutionizing Radiotoxicity Management with Mesenchymal Stem Cells and Their Derivatives: A Focus on Radiation-Induced Cystitis

The document discusses the potential of mesenchymal stem cells (MSCs) and their derivatives in managing radiotoxicity, specifically radiation-induced cystitis. MSCs have regenerative, anti-inflammatory, and anti-fibrotic properties, which make them a promising therapeutic approach for radiation-induced tissue injury. They can differentiate into multiple cell types, self-renew, and secrete growth factors and cytokines involved in tissue repair and regeneration. The document also highlights the therapeutic potential of MSC secretome and extracellular vesicles in various medical applications, including hair follicle regeneration and bladder function improvement in cases of radiation cystitis. However, there are limitations to MSCs' use in clinical practice, including their heterogeneity, risk of immune rejection, potential for tumorigenicity, and potential for differentiation into unwanted cell types. Further research is needed to address these limitations and determine the optimal source of MSCs for different therapeutic applications.